DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DEXCOM INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$85.98−0.06 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $33.54B
- P/E (TTM)
- 34.1
- Dividend yield
- –
DEXCOM INC revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.33B | $2.89B | $2.63B | $2.14B | $1.85B | $1.51B | $1.16B | $818.40M | $596.20M | $497.50M | 71.5% | +15.4% |
| International | $1.33B | $1.14B | $997.00M | $767.80M | $599.10M | $417.20M | $314.50M | $213.20M | $122.30M | $75.80M | 28.5% | +16.1% |
| International [Member] | – | – | – | – | – | – | – | – | $122.30M | $75.80M | – | – |
From the segment and revenue-disaggregation notes of Dexcom's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.